Every biotechnology company begins with optimism.
A scientist discovers something promising. Early laboratory data show potential. Animal studies are encouraging. Investors become interested. Advisors join the board. A company is formed around the belief that the science can improve patients' lives.
That optimism is essential.
The challenge rarely begins with the science.
It begins when scientific potential is converted into a commercial forecast.
Market analyses are commissioned. Pricing consultants estimate reimbursement potential. Epidemiology studies estimate prevalence. Financial models project hundreds of millions of dollars in annual revenue.
Viewed individually, most of these assumptions are reasonable.
The problem is that they rarely account for the commercial friction that exists between identifying a patient and successfully treating that patient.
By the time a therapy reaches the market, the original patient population has often been reduced at every step along the commercialization journey.
Commercial Friction Begins Long Before Launch
Most commercial forecasts assume an ideal healthcare system.
Patients recognize symptoms early.
Primary care physicians suspect the disease.
Specialists confirm the diagnosis.
Genetic testing is readily available.
Centers of Excellence accept referrals promptly.
Insurance approval is straightforward.
Hospitals implement treatment efficiently.
Physicians adopt the new therapy with confidence.
Patients remain on treatment.
In reality, every one of these steps creates friction.
Some patients are never diagnosed.
Others are diagnosed years after symptoms begin.
Some never reach the appropriate specialist.
Insurance requirements delay treatment.
Hospitals struggle with implementation.
Some physicians prefer established therapies while gaining experience with a new treatment.
Individually, these barriers may appear small.
Collectively, they can reduce the commercially treatable population far more than most early forecasts anticipate.
Commercialization Is About Patients You Can Actually Reach
One of the most common mistakes in commercial planning is confusing disease prevalence with the number of patients who are realistically accessible.
Knowing how many patients have a disease is important.
Knowing where those patients receive care is far more valuable.
In many rare diseases, a relatively small number of academic Centers of Excellence manage the majority of diagnosed patients.
That changes the entire commercial strategy.
Success depends less on broad physician awareness and far more on earning the confidence of a limited number of highly specialized physicians, multidisciplinary care teams, hospital administrators, pharmacists, and patient advocacy organizations.
Access to those institutions cannot be assumed. It must be earned.
Development Success and Commercial Success Are Different Objectives
Clinical development and commercialization solve different problems.
Clinical development demonstrates safety and efficacy.
Commercialization ensures that patients actually receive the therapy.
Many biotechnology companies appropriately focus on creating value through successful clinical development before pursuing a partnership or acquisition.
That strategy has created many successful medicines.
However, commercial forecasts sometimes assume that a future commercial organization will effortlessly overcome every barrier involving diagnosis, referrals, institutional access, reimbursement, physician adoption, and long-term persistence.
Experience suggests otherwise.
Commercial execution determines whether clinical success ultimately becomes commercial success.
Every Forecast Should Include Commercial Friction
Commercial forecasts usually begin with total disease prevalence.
They should also account for what happens next.
- How many patients remain undiagnosed?
- How long is the diagnostic journey?
- How many physicians routinely evaluate these patients?
- How many Centers of Excellence account for most treatment decisions?
- How difficult is institutional access?
- What percentage of patients will receive payer approval?
- How many physicians will adopt the therapy during the first three years?
Each answer reduces uncertainty.
Each also refines the commercial opportunity.
The result is often a forecast that is smaller—but considerably more realistic.
The Best Commercial Strategies Challenge Their Own Assumptions
Strong commercial organizations do not simply build optimistic forecasts.
They actively search for the assumptions most likely to fail.
They ask difficult questions long before launch.
- Where are the patients actually receiving care?
- Which physicians influence treatment decisions?
- Which Centers of Excellence account for most referrals?
- What barriers delay diagnosis?
- What evidence will physicians need before changing practice?
- What institutional, operational, or reimbursement obstacles could limit adoption?
These questions are rarely answered in an investor presentation.
They are answered through disciplined commercial planning.
Innovation creates opportunity. Commercial strategy determines how much of that opportunity can realistically be achieved.
